Oncogenic pathway signatures predict the risk of progression and recurrence in well-differentiated pancreatic neuroendocrine tumors.
Michael A MederosColin M CourtBenjamin J DipardoJoseph R PisegnaDavid W DawsonO Joe HinesTimothy R DonahueThomas G GraeberMark D GirgisJames S TomlinsonPublished in: Journal of surgical oncology (2024)
Well-differentiated pNETs are genomically diverse tumors. Pathway signatures may be prognostic for predicting disease progression and recurrence.